Key takeaway: The investor presentation dated July 21, 2026, provided a revised overview of Anthem Biosciences Limited's financial performance for the quarter ended June 30, 2026. The presentation reported consolidated revenue from operations of ₹4,182 million, reflecting a 22.6% decrease year-over-year and a 31.5% decrease quarter-over-quarter. The CRDMO segment generated ₹3,408 million, while the Specialty Ingredients segment contributed ₹774 million. EBITDA was reported at ₹1,755 million with a margin of 39.6%, and profit after tax (PAT) was ₹1,199 million, resulting in a PAT margin of 27.1%. The Chairman, MD, and CEO, Ajay Bhardwaj, noted that the results were influenced by timing shifts in deliveries but emphasized strong underlying demand and a commitment to sustaining revenue growth. The company maintained a net cash position of ₹17,197 million as of June 30, 2026.

Key takeaway: The investor presentation dated July 21, 2026, provided an overview of Anthem Biosciences Limited's financial performance for the quarter ended June 30, 2026. The company reported consolidated revenue from operations of ₹4,182 million, a decrease of 22.6% year-over-year and a 31.5% decline quarter-over-quarter. The CRDMO segment generated ₹3,408 million, while the Specialty Ingredients segment contributed ₹774 million. EBITDA was reported at ₹1,755 million, with EBITDA margins at 39.6%. Profit after tax (PAT) was ₹1,199 million, reflecting an 11.7% decrease year-over-year and a 36.8% decline quarter-over-quarter. The presentation included a message from the Chairman, MD, and CEO, Ajay Bhardwaj, who noted strong underlying demand and a focus on cost efficiencies and productivity to sustain margins. The net cash position as of June 30, 2026, was ₹17,197 million.

Key takeaway: During the earnings conference call held on May 20, 2026, management reported a strong performance for FY26, with consolidated revenue from operations reaching Rs. 2,124 crores, an 18% increase from the previous year. The CRDMO business contributed 83% of this revenue, while specialty ingredients accounted for 17%. EBITDA was reported at Rs. 990 crores, reflecting a 31% growth, with EBITDA margins at 43.4%. The profit after tax for the year was Rs. 592 crores, also a 31% increase. For Q4 FY26, the company achieved its highest revenue quarter ever, with a YoY growth of 26%. Management emphasized their commitment to cost management and sustainable growth, while also discussing future capacity expansions and technology investments. They expressed confidence in maintaining a growth trajectory similar to historical performance, despite not providing specific guidance for FY27 or FY28.

Key takeaway: The investor presentation from Anthem Biosciences Limited reported strong financial performance for the quarter and year ended March 31, 2026. Management highlighted a revenue growth of 26% year-over-year for Q4FY26 and 15% for the full financial year, with the highest revenue quarter recorded. EBITDA and profit after tax (PAT) grew by over 30% for the year. The company maintained a healthy financial position, with EBITDA margins at 43.4% and PAT margins at 26.0% for FY26. Management also noted ongoing construction of a new greenfield facility in Bangalore, with a planned investment of ₹12,000 million. The presentation included details on exceptional items related to new labour codes and their financial impact. Overall, the document emphasized the company's commitment to sustainable growth and profitability across its business segments.

Key takeaway: During the earnings conference call held on February 5, 2026, management reported that Anthem Biosciences Limited achieved consolidated revenue from operations of Rs. 1,513 crore for the nine months ending December 31, 2025, with a significant contribution from the CRDMO business. EBITDA reached Rs. 671 crore, reflecting a margin of 41.5%. Management noted a one-time exceptional item of Rs. 25.4 crore due to new Labor Codes. Profit after tax (PAT) was reported at Rs. 402 crore, with a PAT margin of 24.8%. For Q3 FY26, revenue was Rs. 423 crore, with EBITDA of Rs. 191 crore. Management highlighted a robust underlying demand and expressed confidence in a strong finish for the financial year, despite a lower quarterly performance compared to the previous year due to a high base effect. They guided toward a revenue growth estimate of about 20% for the full year, with EBITDA and PAT margins remaining steady.

Key takeaway: The investor presentation dated February 5, 2026, provided an overview of Anthem Biosciences Limited's financial performance for the quarter and nine months ended December 31, 2025. The presentation reported a consolidated revenue from operations of ₹4,232 million for Q3FY26, a decrease of 15% year-over-year. The CRDMO segment generated ₹3,332 million, while the Specialty Ingredients segment contributed ₹899 million. EBITDA for the quarter was ₹1,907 million, with margins at 41.8%. For the nine-month period, total revenue reached ₹15,134 million, reflecting an 11.2% increase year-over-year. The presentation highlighted an exceptional item of ₹254 million related to changes in wage definitions due to new Labour Codes. The Chairman, MD, and CEO noted steady revenue growth and improving margins, emphasizing robust underlying demand.